Primenenie preparata Esparoksi v lechenii infektsiy LOR-organov


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

The article presents information on the prevalence and etiology of upper respiratory tract infections. The principles of rational choice of antibacterial drugs based on the sensitivity of the main pathogens in otorhinolaryngology are considered. In the treatment of upper respiratory tract infections, particular attention is paid to the potentials for the application of macrolides, particularly roxithromycin (Esparoxy) - oral 14-membered macrolide, combining a wide range of antimicrobial activity, good pharmacokinetic properties, favorable tolerability profile and ease of use (1-2 times a day). To date, experience of treatment with Esparoxy allows to recommend the wider use of this drug in otorhinolaryngology.

Texto integral

Acesso é fechado

Sobre autores

O. Egorova

Bibliografia

  1. Cherry D.K., Hing E., Woodwell D.A., Rechtsteiner E.A. National Ambulatory Medical Care Survey: 2006 Summary. Hyattsville, MD: National Center for Health Statistics; 2008. National health statistics reports.
  2. Available from: http://www.bioanalytical.com/info/calendar/99/03hoech.htm
  3. Bryskier A., Bergogne-Berezin E. Macrolides. In: Antibacterial and antifungal Agents. Bryskier A., editor. ASM-Press (Washington DC), 2005.
  4. Omura S., editor. Macrolide Antibiotics. 2nd edition. Academic Press, 2002.
  5. Available from: http://www.rlsnet.ru/tn_index_id_48528.htm 18.12.2012
  6. Bergan T. Pharmacokinetics of newer macrolides. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu H.C., Young L.S., Zinner S.H., Acar J.F. (Eds.). New York, etc., 1995. P. 51-60.
  7. Begue P., Kafetzis D.A., Albin H., et al. Pharmacokinetics of roxithromycin in paediatrics. J. Antimicrob Chemother. 1987; 20(suppl. B): 101-06.
  8. Hoffler D., Koeppe P., Sorgel F., et al. The pharmacokinetics of roxithromycin in dialysis patient. In: The 18th International Congress of Chemotherapy. Stockholm, 1993: abstr. 260.
  9. Felmingham D., Feldman C., Hryniewicz W., et al. Surveillance of resistance in bacteria causing community-acquired respiratory tract infections. Clin. Microbiol. Infect. 2002; 8(Suppl. 2): 12-42.
  10. Samra Z., Rosenberg S., Kaufman L. Antibiotic susceptibility of Ureaplasma urealyticum. In: The 2nd International Conference on the Macrolides, Azalides and Streptogramins. Venice, 1994: abstr. 146.
  11. Samra Z., Rosenberg S., Soffer Y., et al. In vitro susceptibility of recent clinical isolates of Chlamydia trachomatis to macrolides and tetracyclines. Diagn Microbiol. Infect. Dis. 2001; 39: 177-79.
  12. Goldstein E., Citron D., Vreni Merrinam C., et al. Activities of Telithromycin (HMR 3647, RU 66647) compares to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and other antibacterial agents against unusual anaerobes. Antimicrob Agents Chemother. 1999; 43: 2801-805.
  13. Решедько Г.К., Козлов Р.С. Состояние резистентности к антиинфекционным препаратам в России. В кн.: Страчунский Л.С., Белоусов Ю.Б., Козлов С.Н. Практическое руководство по антиинфекционной химиотерапии. Смоленск, 2007. С. 32-46.
  14. Козлов Р.С., Сивая О.В., Кречикова О.И. и др. Динамика резистентности Streptococcus pneumoniae к антибиотикам в России за период 1999-2009 гг. Клин. микробиол. антимикроб. химиотер. 2010; 4(12): 329-41.
  15. Козлов Р.С. Пневмококки: уроки прошлого -взгляд в будущее. Смоленск, 2010. 128 с.
  16. Методические указания МУК 4.2.1890-04 Определение чувствительности микроорганизмов к антибактериальным препаратам (утв. главным государственным санитарным врачом РФ 04.03.2004).
  17. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2010. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm, 2011.
  18. Веселов А.В. Клинико-фармакологические аспекты практического применения рокситромицина. Фарматека. 2006; 4: 28-37.
  19. Nagino K., Kobayashi H. Influence of macrolides on mucoid alginate biosynthetic enzyme from. Clin. Microbiol. Infect. 1997; 3: 432-39.
  20. Craig W.A., Gudmundson S. Postantibiotic effect. In: Antibiotics in Laboratory Medicine. Lorian V. (Ed.). Baltimore etc., 1996. P. 403-31.
  21. Bergogne-Berezin E. Clinical significance of studies on antibiotic concentrations in the lower respiratory tract. In: Predicting Antibiotic Response in Respiratory Tract Infections. Highlights from the 7th International Congress for Infectious Diseases. Hong Kong, 1996. P. 7-8.
  22. Odenholt-Tornqvist I., Lowdin E., Cars O. Postantibiotic effects and postantibiotic sub-MIC effects of roxithromycin, clarithromycin, and azithromycin on respiratory tract pathogens. Antimicrob. Agents Chemother. 1995; 39: 221-26.
  23. Tateda K., Ishii Y., Matsumoto T., et al. Direct evidence for antipseudomonal activity of macrolides; exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin. Antimicrob. Agents Chemother. 1996; 40: 2271-75.
  24. Chatzimanolis E., Marsan N., Lefatzis D., et al. Comparison of roxithromycin with co-amoxiclav in patients with sinusitis. J. Antimicrob Chemother. 1998; 41(suppl. B): 81-4.
  25. de Campora E., Camaioni A., Leonardi M., et al. Comparative efficacy and safety of roxithromycin and clarithromycin in upper respiratory tract infections. Diagn Microbiol Infect. Dis. 1992; 15(suppl. 4): 119S-22S.
  26. Camaioni A., Leonardi M. Comparative efficacy and safety of roxithromycin and clarithromycin in upper respiratory tract infections. Diagn Microbiol InfectDis 1992; 15(suppl. 4): 119S-22S.
  27. Гаращенко Т.И. Макролиды в терапии острого тонзиллита и его осложнений у детей. РМЖ. 2001; 9(19).
  28. Таточенко В.К., Бакрадзе М.Д. Лихорадка без видимого очага инфекции. Практика педиатра. 2008; 10: 5-11.
  29. Страчунский Л.С., Белоусов Ю.Б., Козлов С.Н. Практическое руководство по антиинфекционной химиотерапии. Смоленск, 2007.
  30. Pichichero M.E., Casey J.R. Systematic review of factors contributing to penicillin treatment failure in Streptococcus pyogenes pharyngitis. Otolaryngol. Head Neck Surg. 2007; 137(6): 851-57.
  31. Kaplan E.L., Johnson D.R. Unexplained reduced microbiological efficacy of intramuscular benzathine penicillin G and of oral penicillin V in eradication of group a streptococci from children with acute pharyngitis. Pediatrics. 2001; 8: 1180-86.
  32. Kaplan E.L., Chhatwal G.S., Rohde M. Reduced ability of penicillin to eradicate ingested group A streptococci from epithelial cells: Clinical and pathogenetic implications. Clin. Infect. Dis. 2006; 43(11): 1398-406.
  33. Carbon C., Hotton J.M., Pepin L.F., et al. Economic analysis of antibiotic regimens used in the treatment pharyngitis: a prospective comparison of azithromycin versus roxithromycin. J. Antimicrob Chemother. 1996; 37(suppl. C): 151-61.
  34. Mira E., Benazzo M. A multicenter study on the clinical efficacy and safety of roxithromycin in the treatment of ear-nose-throat infections: comparison with amoxycillin/clavulanic acid. J. Chemother. 2001; 13: 621-27.
  35. Bazet M.C., Blanc F., Chumdermpadetsuk S., et al. Roxithromycin in the treatment of paediatric infections. Br. J. Clin. Pract. 1988; 42(suppl. 55): 117-18.
  36. Thamlikitkul V., Kobwanthanakun S., Pruksachatvuthi S., et al. Pharmacokinetics of rheumatic fever prophylaxis regimens. J. Int. Med. Res. 1992; 20: 20-6.
  37. Czeizel A.E., Rockenbauer M., Olsen J., et al. A case-control teratological study of spiramycin, roxithromycin, oleandomycin and josamycin. Acta Obstet. Gynecol. Scand. 2000; 79: 234-37.
  38. Karalus N.C., Garrett J.E., Lang S., et al. Roxithromycin 150 mg b.i.d. versus amoxicillin 500 mg/ clavulanic acid 125 mg t.i.d. for the treatment of lower respiratory tract infections in general practice. Infection. 1995; 23: 15-20.
  39. Marsac J.H. An international clinical trial on the efficacy and safety of roxithromycin in 40000 patients with acute community-acquired respiratory tract infections. Diagn Microbiol. Infect. Dis. 1992; 15(suppl. 4): 81S-84S.
  40. Laurencena E., Forti M.J. Roxithromycin in the treatment of acute otitis media in children. Prensa Med. Argent. 1992; 79: 577-79.
  41. Страчунский Л.С., Козлов С.Н. Макролиды в современной клинической практике, 1998. С. 105-20.
  42. Casellas J.M., Rodriguez H.A., Fernandez-Macloughlin G.J., et al. Efficacy of roxithromycin in the treatment of acute otitis media in infants. Br. J. Clin. Pract. 1988; 42(suppl. 55): 113-14.
  43. Stamboulian D., Perianu M. The efficacy of roxithromycin (300 mg once daily or 150 mg BID) in the treatment of «atypical» pneumonia in an international multicentre study. In: The 17th International Congress of Chemotherapy. Berlin, 1991.
  44. Salvarezza C., Villar E., Ballario M. Estudio comparative de la eficacia y tolerancia clinica de roxitromicina vs. amoxicillina en neumopatia extrahospitalarias en pediatria. Prensa Med. Argent. 1989; 76: 127-30.
  45. Ерохин А.И., Гостев М.С. Противомикробный препарат Эспарокси и его применение в стоматологической практике. Клиническая практика. 2010. С. 15.
  46. Deffez J.P., Sheimberg A., Rezvani Y. Milticenter double-blind study of the efficacy and tolerance of roxithromycin versus erythromycin ethylsuccinate in acute orodental infection in adults. Diagn Microbiol. Infect. Dis. 1992; 15: 133S-37S.
  47. Pechere J.-C. Clinical evaluation of roxithromycin 300 mg once daily as an alternative to 150 mg twice daily. Diagn Microbiol. Infect. Dis. 1992; 15(suppl. 4): 111S-17S.
  48. Hopkins S. Clinical toleration and safety of azithromycin. Am. J. Med. 1991; 91(suppl. 3A): 40-5.
  49. Craft J.C., Siepman N. Overview of the safety profile of clarithromycin suspension in pediatric patients. Pediatr. Infect. Dis. J. 1993; 12: 142-47.
  50. Fraschini F. Clinical efficacy and tolerance of two new macrolides, clarithromycin and josamycin, in the treatment of patients with acute exacerbations of chronic bronchitis. J. Int. Med. Res. 1990; 18: 171-76.
  51. Жаркова Л.П. Место рокситромицина в лечении инфекций дыхательных путей. Фарматека. 2013; 4.
  52. Witt A., Sommer E.M., Cichna M., et al. Placental passage of clarithromycin surpasses other macrolide antibiotics. Am. J. Obstet. Gynecol. 2003; 188: 816-19.
  53. Czeizel A.E., Rockenbauer M., Olsen J., et al. A case-control teratological study of spiramycin, roxithromycin, oleandomycin and josamycin. Acta Obste. Gynecol. Scand. 2000; 79: 234-37.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2014

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies